Anteris Technologies Ltd. announced the successful completion of its final chronic animal study required for the FDA early feasibility study (EFS) submission on its proposed US TAVR clinical trial. Formal histopathology results for the three-month study (in six sheep) will be available in approximately four weeks. Its key objectives were to assess (1) DurAVRTM THV hemodynamic performance and the in vivo response. Preliminary findings showed: DurAVRTM THV had fully functioning leaflets and haemodynamics resulting in zero mortalities within the study; and DurAVRTM valve functioned well for the study's duration, including on the following criteria: Healing characteristics (e.g., pannus formation, tissue overgrowth); Effect of post implantation changes in shape and structural components (e.g., the presence of device angulation, bends, kinks) on haemodynamic performance; Haemolysis; Thrombus formation; Embolization of material from the implant site, delivery device or heart valve substitute, migration or embolization of the heart valve substitute; Biological response (e.g., inflammation, calcification, thrombosis, rejection, other unexpected interactions with tissues); Interaction with surrounding anatomical structures (e.g., leaflets, annulus, subvalvular apparatus); and Structural valve deterioration and/or non-structural valve dysfunction.